Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Addex Therapeutics Ltd is a biotechnology business based in the US. Addex Therapeutics shares (ADXN) are listed on the NASDAQ and all prices are listed in US Dollars. Addex Therapeutics employs 27 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$8.51|
|52-week range||$8.88 - $17.98|
|50-day moving average||$9.50|
|200-day moving average||$9.89|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.73|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-5.55%|
|1 month (2021-09-15)||-12.36%|
|3 months (2021-07-15)||-11.81%|
|6 months (2021-04-15)||-16.98%|
|1 year (2020-10-15)||-30.25%|
|2 years (2019-10-11)||N/A|
|3 years (2018-10-11)||N/A|
|5 years (2016-10-11)||N/A|
|Revenue TTM||$4 million|
|Gross profit TTM||$-6,470,057|
|Return on assets TTM||-35.4%|
|Return on equity TTM||-72.5%|
|Market capitalisation||$51.5 million|
TTM: trailing 12 months
There are currently 3,325 Addex Therapeutics shares held short by investors – that's known as Addex Therapeutics's "short interest". This figure is 11.6% down from 3,762 last month.
There are a few different ways that this level of interest in shorting Addex Therapeutics shares can be evaluated.
Addex Therapeutics's "short interest ratio" (SIR) is the quantity of Addex Therapeutics shares currently shorted divided by the average quantity of Addex Therapeutics shares traded daily (recently around 3392.8571428571). Addex Therapeutics's SIR currently stands at 0.98. In other words for every 100,000 Addex Therapeutics shares traded daily on the market, roughly 980 shares are currently held short.
However Addex Therapeutics's short interest can also be evaluated against the total number of Addex Therapeutics shares, or, against the total number of tradable Addex Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Addex Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Addex Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0014% of the tradable shares (for every 100,000 tradable Addex Therapeutics shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Addex Therapeutics.
Find out more about how you can short Addex Therapeutics stock.
We're not expecting Addex Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Addex Therapeutics's shares have ranged in value from as little as $8.88 up to $17.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Addex Therapeutics's is 1.4586. This would suggest that Addex Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. ; Indivior PLC; and The Charcot?Marie?Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.